The growth signal that builds cartilage turns it toward bone when there is too much

Osteoarthritis is not a disease of cartilage alone. This review defines it as a degenerative joint disease marked by the progressive breakdown of cartilage, synovium, and subchondral bone, and synthesises recent foundational and preclinical work on the functional dichotomy of TGF-β signalling at its centre. The common assumption is that more growth signal means more tissue built. In cartilage that equation does not hold.

How does one signal work in both directions?

Because the route splits. At physiological levels, TGF-β signals through SMAD2/3 and promotes chondrocyte anabolism. Under aberrant overactivation, signalling shifts toward the SMAD1/5/8 axis and switches on pathological processes — chondrocyte hypertrophy, synovial fibrosis, and aberrant bone remodeling. Chondrocyte hypertrophy here is nothing like muscle hypertrophy. It is a chondrocyte enlarging as it differentiates toward calcification and ossification: a change in the direction of cartilage disappearing.

Why is this hard to control with a drug?

Because the output is not fixed. The authors describe signalling results as dependent on the specific tissue compartment, disease stage, receptor profile, and local inflammatory microenvironment. An intervention that helps cartilage in early disease can harm the synovium in an advanced joint. Suppressing TGF-β systemically shuts down the protective axis along with the pathological one. The alternative the review sets out is spatiotemporally precise delivery through engineered biomaterials — hydrogels, nanocarriers, and functionalized scaffolds — using controlled release, receptor blockade, or downstream intervention. These strategies remain experimental and preclinical, with joint retention, targeting specificity, long-term biosafety, manufacturing reproducibility, and patient and disease-stage stratification listed as the barriers left.

What does this mean for a lifter?

Two practical conclusions. First, the logic of muscle does not transfer to cartilage. Muscle grows through repeated stimulus and recovery; in cartilage, the moment the growth signal runs too high the tissue shifts toward bone. That is why adding stimulus to a painful knee does not produce the result it produces in muscle. Second, lower expectations for oral supplements and injections marketed as cartilage regeneration. The problem this review identifies is not a missing ingredient — it is that systemic dosing has no precision to separate the two opposing functions of the same molecule. The variable still under your control sits on the load side: a knee-sparing leg setup and training in water when joints hurt.

The point that the local inflammatory environment changes the outcome connects to body fat, systemic inflammation, and joint pain. Read with how body fat relates to joint inflammation and what blood inside a joint does to chondrocytes for why cartilage does not recover the way muscle does.